Ethosuximide
Ethosuximide is the antiepileptic medication that works by blocking T-type calcium channels. This mechanism is well-established and represents its primary mode of action for treating absence seizures 1.
Mechanism of Action
Ethosuximide blocks human T-type calcium channels (Cav3.1, Cav3.2, and Cav3.3) in a state-dependent manner, with higher affinity for inactivated channels 1. The drug achieves therapeutic effects at clinically relevant concentrations:
- Apparent affinity (Ki) for inactivated states: 0.3-1.2 mM depending on the specific T-type channel subtype
- IC50 for persistent current: 0.6 mM
- The active metabolite of methsuximide (alpha-methyl-alpha-phenylsuccinimide) shows similar blocking properties 1
Clinical Context
T-type calcium channels in thalamic neurons contribute to the generation of spike-and-wave discharges characteristic of absence seizures 2, 3. By blocking these channels, ethosuximide:
- Reduces the low threshold calcium spike (LTS) in thalamic neurons
- Dampens rhythmic burst firing patterns
- Suppresses spike-and-wave discharges 2
Other Medications with T-Type Channel Effects
While ethosuximide is the primary T-type calcium channel blocker used clinically, other antiepileptic drugs have varying degrees of T-type channel blocking activity:
- Valproate: Blocks T-type calcium channels but this is not its primary mechanism 4
- Zonisamide: Shows only moderate T-type channel blocking (15-31% reduction at therapeutic concentrations), suggesting this is a minor contributor to its antiepileptic effects 5
Important Distinction
Ethosuximide's specificity for T-type channels distinguishes it from other antiepileptics that have multiple mechanisms of action. This targeted mechanism makes it particularly effective for absence seizures but less useful for other seizure types that don't primarily involve thalamic T-type channel-mediated oscillations.